<code id='F9B665E01E'></code><style id='F9B665E01E'></style>
    • <acronym id='F9B665E01E'></acronym>
      <center id='F9B665E01E'><center id='F9B665E01E'><tfoot id='F9B665E01E'></tfoot></center><abbr id='F9B665E01E'><dir id='F9B665E01E'><tfoot id='F9B665E01E'></tfoot><noframes id='F9B665E01E'>

    • <optgroup id='F9B665E01E'><strike id='F9B665E01E'><sup id='F9B665E01E'></sup></strike><code id='F9B665E01E'></code></optgroup>
        1. <b id='F9B665E01E'><label id='F9B665E01E'><select id='F9B665E01E'><dt id='F9B665E01E'><span id='F9B665E01E'></span></dt></select></label></b><u id='F9B665E01E'></u>
          <i id='F9B665E01E'><strike id='F9B665E01E'><tt id='F9B665E01E'><pre id='F9B665E01E'></pre></tt></strike></i>

          leisure time

          leisure time

          author:fashion    Page View:4
          Cathy McMorris Rodgers -- health policy coverage from STAT
          Rep. Cathy McMorris Rodgers announced her plans to leave Congress at the end of 2024. Anna Moneymaker/Getty Images

          WASHINGTON — Rep. Cathy McMorris Rodgers, the chair of a crucial House committee that handles health care issues, plans to leave Congress at the end of the year, she announced Thursday.

          It will be a major shakeup for a panel already ravaged by Republican retirements. Reps. Michael Burgess (R-Texas), Larry Bucshon (R-Ind.), Jeff Duncan (R-S.C.), Debbie Lesko (R-Ariz.), Greg Pence (R-Ind.) and Kelly Armstrong (R-N.D.) are all leaving at the end of this Congress, too.

          advertisement

          Under McMorris Rodgers, the panel led the way for House passage of a health care price transparency package that included the first major proposal to equalize payment between hospital outpatient departments and physician offices.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Readout LOUD podcast: ALS dilemma, first MASH drug, and more
          Readout LOUD podcast: ALS dilemma, first MASH drug, and more

          Whathappenswhenanapproveddrugdoesn’twork?Whydon’tpatientswantgenetherapy?AndisMASHstillabigdeal?Weco

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

          AdobeAcadiaPharmaceuticalssaidMondaythatitsapprovedmedicinecalledNuplazidfailedtoimprovethesocialand